MagnetisMM-7
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 760 patients (estimated)
- Sponsors
- Pfizer
- Tags
- Bispecific Antibody, GPRC5D
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1322
- NCT Identifier
- NCT05317416
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.